Between August 2024 and August 2025, around 63% of the novel drugs approved in the US received an expedited regulatory review, compared to around just 4% in the EU. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
